|
|
Article: Hybridon Presents Data on Activity of Immunomodulatory Oligonucleotides In Preclinical Models of Allergic Asthma.
- Article from:
- PR Newswire
- Article date:
- March 11, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Hybridon, Inc. (BULLETIN BOARD: HYBN.OB) announced today the presentation of preclinical studies of the use of its immunomodulatory oligonucleotides (IMO(TM)) in allergic asthma models. The presentation was made at the 60th annual meeting of the American Academy of Allergy, Asthma and Immunology being held in Denver, CO. The presentation entitled: "Down-regulation of Th2 cytokines in vitro by immunomodulatory oligonucleotides (IMO(TM)) containing modified CpG motifs" is authored by Drs. K.D. Srivastava, H.A. Sampson, and X.-M. Li of the Mount Sinai School of Medicine, New York, and Drs. E.R. Kandimalla, D. Yu and S. Agrawal of Hybridon, Inc.
This study ...